AN4035 / Adlai Nortye - LARVOL DELTA

Discovery of AN4035: A novel CEACAM5-targeting antibody drug conjugate (ADC) armed with a proprietary pan-RAS(ON) inhibitor payload, designed to broaden the therapeutic window (AACR-NCI-EORTC 2025) - "Although the tricomplex pan-RAS(ON) inhibitor RMC-6236 has demonstrated promising antitumor activity in clinical studies, its therapeutic potential is challenged by presumably on-target, off-tumor toxicities, particularly in skin and gastrointestinal (GI) tissues. These findings support the further development of AN4035 as a promising first-in-class ADC for RAS-driven, CEACAM5-expressing cancers. IND-enabling studies are currently underway."

Oncology • Pancreatic Cancer • CEACAM5 • KRAS • TOP1

Discovery of AN4035: A Novel CEACAM5-Targeting Antibody Drug Conjugate (ADC) Armed with a Proprietary Pan-RAS(ON) Inhibitor Payload, Designed to Broaden the Therapeutic Window (AACR-NCI-EORTC 2025) - "Although the tricomplex pan-RAS(ON) inhibitor RMC-6236 has demonstrated promising antitumor activity in clinical studies, its therapeutic potential is challenged by presumably on-target, off-tumor toxicities, particularly in skin and gastrointestinal (GI) tissues. These findings support the further development of AN4035 as a promising first-in-class ADC for RAS-driven, CEACAM5-expressing cancers. IND-enabling studies are currently underway."

Late-breaking abstract • Oncology • Pancreatic Cancer • CEACAM5 • KRAS • TOP1